P. Schellhammer

发表

Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine.

G. Wright, S. Nasim, L. Gong, 2001, The American journal of pathology.

Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men.

P. Schellhammer, Y. Yasui, B. Adam, 2002, Cancer research.

Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients.

P. Schellhammer, Y. Yasui, B. Adam, 2002, Clinical chemistry.

Failure of anticytokeratin 18 antibody to improve flow cytometric detection of bladder cancer

P. Schellhammer, George L. Wright, A. Konchuba, 1992, Cancer.

Flow cytometric DNA analysis after immunoselection of bladder tumor cells with monoclonal antibody DU83.21

P. Schellhammer, George L. Wright, A. Konchuba, 1990, Cancer.

Flow cytometric study comparing paired bladder washing and voided urine for bladder cancer detection.

P. Schellhammer, George L. Wright, A. Konchuba, 1989, Urology.

Protein Profiling in Urine for the Diagnosis of Bladder Cancer

A. Vlahou, P. Schellhammer, F. Kondylis, 2004 .

Data Reduction Using a Discrete Wavelet Transform in Discriminant Analysis of Very High Dimensionality Data

P. Schellhammer, J. Potter, Y. Yasui, 2003, Biometrics.

Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

P. Kantoff, P. Schellhammer, C. Redfern, 2010, The New England journal of medicine.

Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer.

P. Schellhammer, R. deVere White, J. Sheinfeld, 1995, The Journal of urology.

Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group.

P. Schellhammer, G. Kennealey, N. Vogelzang, 1995, Urology.

Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study.

P. Schellhammer, S. Culp, Michael Williams, 2014, European urology.

Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline.

T. Wilt, B. Kramer, P. Schellhammer, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Major rectal complications following interstitial implantation of 125iodine for carcinoma of the prostate.

P. Schellhammer, G. Jordan, D. Lynch, 1985, The Journal of urology.

Identification of a superimmunoglobulin gene family member overexpressed in benign prostatic hyperplasia

B. Adam, P. Schellhammer, B. Adam, 2000, The Prostate.

Prostate-specific Membrane Antigen Levels in Sera from Healthy Men and Patients with Benign Prostate Hyperplasia or Prostate Cancer 1

A. Vlahou, P. Schellhammer, George L. Wright, 1999 .

Prostate-specific membrane antigen levels in sera from healthy men and patients with benign prostate hyperplasia or prostate cancer.

A. Vlahou, P. Schellhammer, L. Cazares, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Radical Retropubic Prostatectomy

P. Schellhammer, John W. Davis, 2003 .

Prostate-specific antigen after radiation therapy. Prognosis by pretreatment level and post-treatment nadir.

D. Kuban, P. Schellhammer, G. Wright, 1997, The Urologic clinics of North America.

Pathological findings after preoperative irradiation for carcinoma of the urinary bladder.

P. Schellhammer, A. El-Mahdi, W. Peeples, 1979, Radiology.

Prostatic involvement by transitional cell carcinoma: pathogenesis, patterns and prognosis.

P. Schellhammer, W. Whitmore, M. Bean, 1977, The Journal of urology.

Life after failure of traditional androgen deprivation therapy.

P. Schellhammer, 2012, Urologic oncology.

Combined androgen blockade: the case for bicalutamide.

P. Schellhammer, L. Klotz, 2005, Clinical prostate cancer.

A re‐assessment of the role of combined androgen blockade for advanced prostate cancer

P. Schellhammer, L. Klotz, K. Carroll, 2004, BJU international.

Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review.

T. Wilt, P. Schellhammer, E. Crawford, 2001, Urology.

Luteinizing hormone-releasing hormone monotherapy: a viable option for treatment of prostate cancer?

P. Schellhammer, 2001, Urology.

Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade.

P. Schellhammer, G. Haas, E. Klein, 1997, The Journal of urology.

Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study.

P. Schellhammer, C. Roehrborn, M. Resnick, 2000, The Journal of urology.

Zoladex versus orchiectomy in treatmentof advanced prostate cancer: a randomized trial

P. Schellhammer, Joseph A. Smith, N. Vogelzang, 1991 .

The durability of external beam radiation therapy for prostate cancer: can it be identified?

D. Kuban, P. Schellhammer, P. Kolm, 1999, The Journal of urology.

Quality of life after sipuleucel-T therapy: results from a randomized, double-blind study in patients with androgen-dependent prostate cancer.

P. Schellhammer, D. Penson, L. M. Glodé, 2013, Urology.

Witnessing the Transition of Open to Robotic Surgery

P. Schellhammer, M. Fabrizio, J. Malcolm, 2011 .

Guideline for the Management of Nonmuscle Invasive Bladder Cancer : ( Stages Ta , T 1 , and Tis ) : 2007 Update Bladder Cancer

P. Schellhammer, J. Seigne, R. Pruthi, 2014 .

Carcinoma of the prostate: race as a prognostic indicator in definitive radiation therapy.

D. Kuban, P. Schellhammer, A. El-Mahdi, 1995, Radiology.

Malignant pericardial effusion as initial solitary site of metastasis from transitional cell carcinoma of the bladder.

P. Schellhammer, J. Newton, S. Fabozzi, 1995, Urology.

Voiding impairment after prostate biopsy: does tamsulosin treatment before biopsy decrease this morbidity?

P. Schellhammer, E. Akbay, E. Ulusoy, 2003, Urology.

Laparoscopic radical prostatectomy: evaluation of specimen pathologic features to critically assess and modify surgical technique.

P. Schellhammer, M. Fabrizio, D. Rabah, 2005, Urology.

Sural nerve graft during laparoscopic radical prostatectomy. Initial experience.

P. Schellhammer, S. Loening, John W. Davis, 2002, Urologic oncology.

Practical system of assessment: an updated acronym for PSA.

P. Schellhammer, 2007, The Journal of urology.

Superficial bladder carcinoma treated with bacillus Calmette-Guerin: progression-free and disease specific survival with minimum 10-year followup.

P. Schellhammer, John W. Davis, Seemit I Sheth, 2002, The Journal of urology.

Sipuleucel-T

P. Kantoff, P. Schellhammer, C. Higano, 2020, Reactions Weekly.

Orthotopic treatment model of prostate cancer and metastasis in the immunocompetent mouse: Efficacy of flt3 ligand immunotherapy

P. Schellhammer, George L. Wright, Nazita Yousefieh, 2003, International journal of cancer.

Glycomic characterization of prostate-specific antigen and prostatic acid phosphatase in prostate cancer and benign disease seminal plasma fluids.

Mary Ann Comunale, P. Schellhammer, M. Clements, 2009, Journal of proteome research.

Reply to P.C. Walsh

B. Kramer, P. Schellhammer, M. Somerfield, 2009 .

‘Should I get a PSA test?’ – the question is not that simple

P. Schellhammer, P. Lange, J. Montie, 2015 .

The Prognostic Significance of S–Phase Analysis in Stage Ta/T1 Bladder Cancer

P. Schellhammer, E. Messing, A. Sagalowsky, 2000, European Urology.

An update on bicalutamide in the treatment of prostate cancer.

P. Schellhammer, 1999, Expert opinion on investigational drugs.

5‐α‐Reductase inhibitors for prostate cancer chemoprevention: an updated Cochrane systematic review

T. Wilt, R. MacDonald, B. Kramer, 2010, BJU international.

Use of 5-α-Reductase Inhibitors for Prostate Cancer Chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline Summary.

T. Wilt, B. Kramer, P. Schellhammer, 2009, Journal of oncology practice.

Words of wisdom. Re: Pathologic characteristics of cancers detected in the Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention.

P. Schellhammer, 2009, European urology.

Use of 5alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline.

T. Wilt, B. Kramer, P. Schellhammer, 2009, The Journal of urology.

Editorial: Improving outcomes for primary and salvage therapy of localized prostate cancer.

P. Schellhammer, 2003, The Journal of urology.

Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy?

Ximing J. Yang, P. Schellhammer, J. Epstein, 1999 .

Exploratory analysis on the effect of race on clinical outcome in patients with advanced prostate cancer receiving bicalutamide or flutamide, each in combination with LHRH analogues

P. Schellhammer, N. Vogelzang, M. Soloway, 1999, The Prostate.

A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group.

P. Schellhammer, N. Vogelzang, M. Soloway, 1995, Urology.

Contemporary expectant therapy series: A viewpoint

P. Schellhammer, 1994 .

Editorial: Where Treatment May Be Necessary and Possible

P. Schellhammer, 1994 .

Prostate-specific antigen for pretreatment prediction and posttreatment evaluation of outcome after definitive irradiation for prostate cancer.

D. Kuban, P. Schellhammer, A. El-Mahdi, 1995, International journal of radiation oncology, biology, physics.

Normal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ionization mass spectrometry.

O John Semmes, Bao-Ling Adam, Lisa H Cazares, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Application of a novel protein chip mass spectrometry technology for the identification of bladder cancer-associated biomarkers.

Antonia Vlahou, A. Vlahou, P. Schellhammer, 2003, Advances in experimental medicine and biology.

Free and complexed prostate-specific antigen serum ratios to predict probability of primary prostate cancer and benign prostatic hyperplasia.

M. Kattan, P. Schellhammer, R. Vessella, 1996, Urology.

Laparoscopic Radical Prostatectomy

P. Schellhammer, M. Fabrizio, D. Soderdahl, 2004 .

Results of radical prostatectomy in men with clinically localized prostate cancer.

P. Schellhammer, P. Scardino, R. Thisted, 1996, JAMA.

Results of radical prostatectomy in men with clinically localized prostate cancer.

J A Smith, P. Schellhammer, P. Scardino, 1996, JAMA.

Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer.

P. Schellhammer, M. Lieber, M. Soloway, 2002, The Journal of urology.

Two-site monoclonal antibody-based immunoradiometric assay for measuring prostate secretory protein in serum.

P. Schellhammer, G. Wright, M. L. Beckett, 1992, Clinical chemistry.

Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens

P. Schellhammer, J. Moul, C. Higano, 2018, The Journal of urology.

A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone–Releasing hormone analogue therapy, in patients with advanced prostate carcinoma: Analysis of time to progression

P. Schellhammer, N. Vogelzang, Yusong Chen, 1996, Cancer.

Monoclonal Antibody PD 41 Recognizes an Antigen Restricted to Prostate Adenocarcinomas 1

P. Schellhammer, George L. Wright, G. Lipford, 2006 .

Isolation of a soluble tumor-associated antigen from human renal cell carcinoma by gradient acrylamide gel electrophoresis.

P. Schellhammer, G. Wright, R. Faulconer, 1977, Cancer research.

Prostate-specific antigen after radiation therapy : Prognosis by pretreatment level and post-treatment nadir : Prostate-specific antigen: the best prostatic tumor marker

D. Kuban, P. Schellhammer, George L. Wright, 1997 .

Effects of the calcium influx inhibitor carboxyamido‐triazole on the proliferation and invasiveness of human prostate tumor cell lines

E. Kohn, P. Schellhammer, J. Rhim, 1996, International journal of cancer.

Bicalutamide in the treatment of advanced prostatic carcinoma: a phase II noncomparative multicenter trial evaluating safety, efficacy and long-term endocrine effects of monotherapy.

P. Schellhammer, N. Vogelzang, M. Soloway, 1995, The Journal of urology.

Drug Evaluation Oncologic, Endocrine & Metabolic: Bicalutamide (Casodex™)

P. Schellhammer, 1996 .

Serum levels of endothelial and neural cell adhesion molecules in prostate cancer

P. Schellhammer, George L. Wright, M. Clements, 1997, The Prostate.

Quality of life after treatment for localized prostate cancer: differences based on treatment modality.

D. Kuban, P. Schellhammer, D. Lynch, 2001, The Journal of urology.

Prostate Tumor Microenvironment Alters Immune Cells and Prevents Long-Term Survival in an Orthotopic Mouse Model Following flt3-Ligand/CD40-Ligand Immunotherapy

P. Schellhammer, George L. Wright, Nazita Yousefieh, 2004, Journal of immunotherapy.

Urologic aspects of pancreatic adenocarcinoma.

P. Schellhammer, S. Warden, J. Fiveash, 1981, Journal of Urology.

[Comparative study of surgical efficacy in open versus laparoscopic prostatectomy: virtual prostate reconstruction and periprostatic tissue quantification].

P. Schellhammer, R. Mckenzie, A. Corica, 2007, Actas urologicas espanolas.

Quality of life after open or robotic prostatectomy, cryoablation or brachytherapy for localized prostate cancer

P. Schellhammer, John W. Davis, M. Fabrizio, 2011 .

The effect of prior transurethral resection of the prostate on post radiation urethral strictures and bladder neck contractures.

P. Schellhammer, A. El-Mahdi, C. Seymore, 1986, International journal of radiation oncology, biology, physics.

Comparison of goserelin and leuprolide in combined androgen blockade therapy.

P. Schellhammer, E. Klein, N. Vogelzang, 1998, Urology.

Characteristics of spinal cord compression in adenocarcinoma of prostate.

D. Kuban, P. Schellhammer, A. El-Mahdi, 1986, Urology.

Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study.

P. Schellhammer, E. Messing, D. Lamm, 1995, Urologic oncology.

Immunotherapy with autologous antigen presenting cells for the treatment of androgen independent prostate cancer

P. Schellhammer, R. Hershberg, 2005, World Journal of Urology.

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.

P. Schellhammer, C. Redfern, J. Nemunaitis, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized Trial of Autologous Cellular Immunotherapy with Sipuleucel-T in Androgen-Dependent Prostate Cancer

P. Schellhammer, L. M. Glodé, T. Beer, 2011, Clinical Cancer Research.

Leukocyte migration inhibition assay in patients with prostate adenocarcinoma

P. Schellhammer, George L. Wright, G. Wright, 1981, The Prostate.

Leukocyte migration inhibition assay in patients with bladder cancer.

P. Schellhammer, G. Wright, F. Rosato, 1979, The Journal of urology.

Cell-mediated immunity in patients with renal cell carcinoma as measured by leukocyte migration inhibition test.

P. Schellhammer, G. Wright, F. Rosato, 1978, Urology.

Metastatic castrate-resistant prostate cancer.

P. Schellhammer, 2015, Urologic oncology.

Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer.

P. Kantoff, P. Schellhammer, C. Higano, 2012, Journal of the National Cancer Institute.

Intravesical chemotherapy and immunotherapy for superficial tumors Basic mechanism of action and future direction.

P. Schellhammer, J. Witjes, K. Kurth, 1998, Urologic oncology.

Bilateral testicular lymphoma treated with chemotherapy and radiation without orchiectomy: complete response relapsed at 52 months in the vitreous humor.

P. Schellhammer, S. Schlossberg, J. W. Davis, 2001, Urology.

Comparison of prostate secretory protein with prostate specific antigen and prostatic acid phosphatase as a serum biomarker for diagnosis and monitoring patients with prostate carcinoma

P. Schellhammer, George L. Wright, G. Wright, 1993, The Prostate.

Prostate specific antigen levels after definitive irradiation for carcinoma of the prostate.

P. Schellhammer, S. Schlossberg, G. Wright, 1991, The Journal of urology.

Radical Retropubic Prostatectomy

P. Schellhammer, John W. Davis, 2003 .

Should we delay prostate radiotherapy?

P. Schellhammer, J. P. Petersen, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Conservative surgical therapy for penile and urethral carcinoma.

P. Schellhammer, S. Schlossberg, J. W. Davis, 1999, Urology.

Paraganglioma of urinary bladder in patient with neurofibromatosis.

P. Schellhammer, D. Weaver, E. Burton, 1986, Urology.

Spontaneous regression of metastatic renal cell carcinoma.

P. Schellhammer, R. Snow, R. Snow, 1982, Urology.

THERAPY FOR ADVANCED AND HORMONE REFRACTORY CANCER OF THE PROSTATE

K. Pienta, P. Schellhammer, 2000 .

PSA response to secondary androgen deprivation following failed treatment of metastatic prostate cancer with the antiandrogen casodex.

P. Schellhammer, P. Kolm, S. Fabozzi, 1995, Urologic oncology.

Calcium signaling in prostate cancer cells: Evidence for multiple receptors and enhanced sensitivity to bombesin/GRP

P. Schellhammer, J. Rhim, George L. Wright, 1997, The Prostate.

Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer: will more prove better?

P. Schellhammer, 1998, International journal of radiation oncology, biology, physics.

Management of bleeding renal angiomyolipomas by transcatheter embolization following CT diagnosis

John C. Schaefer, P. Schellhammer, E. Zerhouni, 1984, Urologic radiology.

Immunohistochemical Localization of Prostate Carcinoma-associated Antigens1

P. Schellhammer, George L. Wright, J. J. Starling, 2006 .

Immunohistochemical localization of prostate carcinoma-associated antigens.

P. Schellhammer, G. Wright, J. J. Starling, 1983, Cancer research.

Prognostic significance of DNA ploidy in Ta/Tl bladder cancer: A southwest oncology group study.

P. Schellhammer, E. Messing, E. Crawford, 1996, Urologic oncology.

The effect of TURP on prognosis in prostatic carcinoma.

D. Kuban, P. Schellhammer, A. El-Mahdi, 1986, International journal of radiation oncology, biology, physics.

The effect of transurethral prostatic resection on the incidence of osseous prostatic metastasis

D. Kuban, P. Schellhammer, A. El-Mahdi, 1985, Cancer.

Biomolecular and clinical characteristics of PSA and other candidate prostate tumor markers.

P. Schellhammer, G. Wright, 1993, The Urologic clinics of North America.

Overexpression of p53 in prostate carcinoma is associated with improved overall survival but not predictive of response to radiotherapy.

D. Kuban, P. Schellhammer, L. Cazares, 2000, International journal of oncology.

Bicalutamide in the treatment of advanced prostatic carcinoma: a phase II multicenter trial.

P. Schellhammer, M. Soloway, G. Chodak, 1996, Urology.

Does prolonged combined androgen blockade have survival benefits over short-term combined androgen blockade therapy?

P. Schellhammer, M. Sarosdy, K. Carroll, 2000, Urology.

Development of a scale to assess patient misperceptions about treatment choices for localized prostate cancer

P. Schellhammer, John W. Davis, H. Beydoun, 2010, BJU international.

Prognostic significance of post-irradiation prostate biopsies.

D. Kuban, P. Schellhammer, A. El-Mahdi, 1993, Oncology.

Monoclonal Antibodies to Human Prostate and Bladder Tumor-associated Antigens1

P. Schellhammer, George L. Wright, J. J. Starling, 2006 .

Local failure and related complications after definitive treatment of carcinoma of the prostate by irradiation or surgery.

P. Schellhammer, A. El-Mahdi, 1990, The Urologic clinics of North America.

Outcomes after intravesical bacillus Calmette-Guerin are not affected by substaging of high grade T1 transitional cell carcinoma.

P. Schellhammer, F. Kondylis, P. Kolm, 2000, The Journal of urology.

Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? PLESS Study Group. Proscar Long-Term Efficacy and Safety Study.

P. Schellhammer, J. Epstein, J. Gottesman, 1999, Urology.

A phase III randomized trial of intermittent versus continuous androgen suppression for PSA progression after radical therapy (NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/ UK Intercontinental Trial CRUKE/01/013).

P. Schellhammer, F. Saad, J. Chin, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study.

P. Schellhammer, C. Roehrborn, M. Resnick, 2000, The Journal of urology.

Additional bacillus Calmette-Guérin therapy for recurrent transitional cell carcinoma after an initial complete response.

P. Schellhammer, T. Bui, 1997, Urology.

Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease.

P. Schellhammer, E. Dalmasso, B. Adam, 2001, Cancer research.

5-a-Reductase inhibitors for prostate cancer chemoprevention: An updated Cochrane systematic review (BJU International (2010) 106:10 (1444-1451))

T. Wilt, R. MacDonald, B. Kramer, 2011 .

An evaluation of bicalutamide in the treatment of prostate cancer

P. Schellhammer, Paul F Schellhammer, 2002, Expert opinion on pharmacotherapy.

Intermittent versus continuous androgen deprivation in prostate cancer.

Donna L Berry, Ian M Thompson, Stephen Prescott, 2013, The New England journal of medicine.

Intermittent androgen suppression for rising PSA level after radiotherapy.

Fred Saad, Emma Hall, Graeme Duncan, 2012, The New England journal of medicine.

Conservative management of prostate cancer in the prostate specific antigen era: the incidence and time course of subsequent therapy.

P. Schellhammer, A. Zietman, P. Schellhammer, 2001, The Journal of urology.

Changes in immunohistochemical staining of PSA, PAP, and TURP-27 following irradiation therapy for clinically localized prostate cancer.

P. Schellhammer, G. Wright, B. Grob, 1994, Urology.

Prostate-specific antigen to determine progression-free survival after radiation therapy for localized carcinoma of prostate.

P. Schellhammer, George L. Wright, P. Kolm, 1993, Urology.

The use of microsurgical denervation of the spermatic cord for orchialgia.

P. Schellhammer, C. Devine, 1978, Transactions of the American Association of Genito-Urinary Surgeons.

External sphincterotomy: an evaluation of 150 patients with neurogenic bladder.

P. Schellhammer, R. C. Bunts, R. Hackler, 1973, The Journal of urology.

Prostatic carcinoma with cutaneous metastases.

P. Schellhammer, R. C. Bunts, R. Milsten, 1973, British journal of urology.

Premalignant lesions and nonsquamous malignancy of the penis and carcinoma of the scrotum.

P. Schellhammer, G. Jordan, J. Spaulding, 1992, The Urologic clinics of North America.

Upper tract urothelial malignancy after cyclophosphamide therapy: a case report and literature review.

P. Schellhammer, D. W. Brenner, 1987, The Journal of urology.

Cancer serum index and prostatic acid phosphatase for detection of progressive prostatic cancer.

P. Schellhammer, G. Wright, A. El-Mahdi, 1985, The Journal of urology.

Comparison of countercurrent immunoelectrophoretic assay with commercial radioimmunoassay kits for measuring prostatic acid phosphatase.

P. Schellhammer, G. Wright, M. Leffell, 1981, Clinical chemistry.

Testicular and Penile Cancer

P. Schellhammer, John W. Davis, D. Lynch, 2007 .

Monoclonal antibody PD41 recognizes an antigen restricted to prostate adenocarcinomas.

P. Schellhammer, G. Wright, G. Lipford, 1991, Cancer research.

Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy.

P. Schellhammer, George L. Wright, D. Petrylak, 1996, Urology.

Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system.

P. Schellhammer, J. Oesterling, R. Vessella, 1997, Urology.

Radioimmunoassay versus counterimmune electrophoresis for measurement of serum prostatic acid phosphatase.

P. Schellhammer, G. Wright, M. Leffell, 1982, Urology.

Bone marrow and acid phosphatase by counterimmune electrophoresis: pre-treatment and post-treatment correlations.

P. Schellhammer, G. Wright, S. Warden, 1982, The Journal of urology.

Monoclonal antibodies to human prostate and bladder tumor-associated antigens.

P. Schellhammer, George L. Wright, G. Wright, 1982, Cancer research.

Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues.

P. Schellhammer, George L. Wright, G. Wright, 1995, Urologic oncology.

Intravesical bacillus Calmette-Guerin for the treatment of superficial transitional cell carcinoma of the prostatic urethra in association with carcinoma of the bladder.

P. Schellhammer, R. Moriarty, L. Ladaga, 1995, The Journal of urology.

Superficial transitional cell carcinoma of the bladder associated with mucosal involvement of the prostatic urethra: results of treatment with intravesical bacillus Calmette-Guerin.

P. Schellhammer, L. Ladaga, R. W. Hillyard, 1988, The Journal of urology.

Half-body irradiation for treatment of widely metastatic adenocarcinoma of the prostate.

D. Kuban, P. Schellhammer, A. El-Mahdi, 1989, The Journal of urology.

Malignant epithelial tumours

P. Schellhammer, G. Krogh, V. Reuter, 2006 .

The treatment of choice for localized poorly differentiated adenocarcinoma of the prostate

D. Kuban, P. Schellhammer, A. El-Mahdi, 1985, American journal of clinical oncology.

Bropirimine immunotherapy of upper urinary tract carcinoma in situ.

P. Carroll, P. Schellhammer, D. Lamm, 1996, Urology.

Oral bropirimine immunotherapy of carcinoma in situ of the bladder: results of a phase II trial.

P. Schellhammer, D. Lamm, H. Grossman, 1996, Urology.

Cytogenetic evaluation of 20 cultured primary prostatic tumors.

P. Schellhammer, J. McNeal, D. Peehl, 1991, Cancer genetics and cytogenetics.

605: Androgen Independent Prostate Cancer (AIPC) Patients who Receive Sipuleucel-T Followed by Docetaxel Have Prolonged Survival

P. Schellhammer, E. Small, D. Petrylak, 2007 .

Results of a placebo-controlled phase III trial of immunotherapy with APC8015 for patients with hormone refractory prostate cancer (HRPC)

P. Schellhammer, C. Higano, E. Small, 2005 .

Role of estrogen in normal male function: clinical implications for patients with prostate cancer on androgen deprivation therapy.

P. Schellhammer, R. Wassersug, E. Wibowo, 2011, The Journal of urology.

Radical prostatectomy. Patterns of local failure and survival in 67 patients.

P. Schellhammer, 1988, Urology.

Integrated data from 2 randomized, double‐blind, placebo‐controlled, phase 3 trials of active cellular immunotherapy with sipuleucel‐T in advanced prostate cancer

P. Schellhammer, J. Nemunaitis, C. Higano, 2009, Cancer.

Malignant epithelial tumors

P. Schellhammer, G. Krogh, V. Reuter, 2004 .

Human prostate tissue antigens defined by murine monoclonal antibodies.

P. Schellhammer, G. Wright, J. J. Starling, 1986, Cancer research.

Consensus statement: Guidelines for PSA following radiation therapy

James D. Cox, David J. Grignon, James T. Parsons, 1997 .

Experience with transureteroureterostomy in the paraplegic patient with irreversible vesicoureteral reflux.

P. Schellhammer, R. Hackler, R. Malkin, 1974, The Journal of urology.

Re: Intravesical bacillus Calmette-Guerin therapy and associated granulomatous renal masses.

P. Schellhammer, 1987, The Journal of urology.

Bacillus Calmette-Guerin therapy for high risk stage T1 superficial bladder cancer.

P. Schellhammer, G. Eure, M. Cundiff, 1992, The Journal of urology.

Bacillus Calmette-Guerin for superficial transitional cell carcinoma of the bladder.

P. Schellhammer, L. Ladaga, M. Fillion, 1986, The Journal of urology.

A phase II clinical trial of oral bropirimine in combination with intravesical bacillus Calmette-Guérin for carcinoma in situ of the bladder: a Southwest Oncology Group Study.

P. Schellhammer, C. Tangen, A. Sagalowsky, 2005, Urologic oncology.

Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update.

P. Schellhammer, Sam S. Chang, J. Seigne, 2007, The Journal of urology.

Renal failure associated with the use of thio-tepa.

P. Schellhammer, 1973, The Journal of urology.

Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference.

Paul Schellhammer, P. Schellhammer, H. Sandler, 2006, International journal of radiation oncology, biology, physics.

Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institutional pooled analysis.

P. Schellhammer, P. Scardino, R. Thisted, 1997, European urology.

Estrogen receptor activity in a case of Hodgkin's disease.

P. Schellhammer, J. Lloyd, J. Stark, 1981, Annals of internal medicine.

Effect of local tumor control on distant metastasis and survival in prostatic adenocarcinoma.

D. Kuban, P. Schellhammer, A. El-Mahdi, 1987, Urology.

A mode of treatment for incarceration of the penis.

P. Schellhammer, J. Donnelly, 1973, The Journal of trauma.

Timing of androgen deprivation therapy: some questions answered, others not.

P. Schellhammer, 2006, Journal of the National Cancer Institute.

Patients’ Survival Expectations before Localized Prostate Cancer Treatment by Treatment Status

P. Schellhammer, John W. Davis, H. Beydoun, 2009, The Journal of the American Board of Family Medicine.

Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial.

P. Kantoff, P. Schellhammer, G. Chodak, 2013, Urology.

Bicalutamide and Flutamide, Each in Combination with Luteinizing Hormone-Releasing Hormone Analogs, in Advanced Prostate Cancer: Exploratory Analysis of Impact of Extent of Disease by Bone Scan on Outcome

P. Schellhammer, N. Vogelzang, M. Soloway, 2000 .

Oncodiagnosis panel: 1997. Prostatic carcinoma

Deborah A. Kuban, David J. Grignon, Jeffrey H. Newhouse, 1999 .

Comparative quality-of-life analysis after radical prostatectomy or external beam radiation for localized prostate cancer.

P. Schellhammer, P. Kolm, K. McCammon, 1999, Urology.

Steroid therapy for ureteral obstruction after aortoiliac graft surgery.

P. Schellhammer, R. Huben, 1981, The Journal of urology.

Prospective longitudinal comparative study of early health-related quality-of-life outcomes in patients undergoing surgical treatment for localized prostate cancer: a short-term evaluation of five approaches from a single institution.

P. Schellhammer, John W. Davis, M. Fabrizio, 2006, Journal of endourology.

Mortality associated with feeding catheter jejunostomy after radical cystectomy.

P. Schellhammer, D. W. Brenner, 1987, Urology.

Long-term follow-up of intravesical bacillus Calmette-Guérin treatment for superficial transitional-cell carcinoma of the bladder involving the prostatic urethra.

P. Schellhammer, John W. Davis, Jonathan H. Taylor, 2007, Clinical genitourinary cancer.

Treatment of clinical local failure after radiation therapy for prostate carcinoma.

D. Kuban, P. Schellhammer, A. El-Mahdi, 1993, The Journal of urology.

Open Label Phase II Study of Enzalutamide With Concurrent Administration of Radium 223 Dichloride in Patients With Castration-Resistant Prostate Cancer.

P. Schellhammer, N. Shore, N. Mariados, 2020, Clinical genitourinary cancer.

Intravesical dimethyl sulfoxide for primary amyloidosis of the bladder.

P. Schellhammer, K. McCammon, R. Moriarty, 1998, Urology.

Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group.

P. Schellhammer, N. Vogelzang, M. Soloway, 1997, Urology.

A controlled trial of Casodex (bicalutamide) vs. flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Casodex Combination Study Group.

P. Schellhammer, N. Vogelzang, M. Soloway, 1996, European urology.

Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group.

P. Schellhammer, N. Vogelzang, M. Soloway, 1996, Urology.

The adrenal gland and renal cell carcinoma: is ipsilateral adrenalectomy a necessary component of radical nephrectomy?

P. Schellhammer, E. Robey, 1986, The Journal of urology.

Transitional cell carcinoma and renal cell adenocarcinoma in single kidney.

P. Schellhammer, B. Fallon, 1975, Urology.

Renal cell carcinoma with solitary metastases to pericardium.

P. Schellhammer, A. El-Mahdi, 1983, Urology.

Suprarenal Greenfield filter placement to prevent pulmonary embolus in patients with vena caval tumor thrombi.

P. Schellhammer, J. Granger, J. Scott, 1992, The Journal of urology.

Repair of obliterative vesicourethral stricture after radical prostatectomy: a technique for preservation of continence.

P. Schellhammer, G. Jordan, S. Schlossberg, 1995, Urology.

Protein profiling of urine in the diagnosis of bladder cancer

O John Semmes, Antonia Vlahou, A. Vlahou, 2005, Nature Clinical Practice Urology.

Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry

P. Kantoff, M. Cooperberg, P. Schellhammer, 2020, Prostate Cancer and Prostatic Diseases.

Helping Patients Make Treatment Choices for Localized Prostate Cancer

P. Schellhammer, H. Beydoun, R. Mohan, 2012 .

Treatment options for localized prostate cancer.

P. Schellhammer, Paul F Schellhammer, R. Mohan, 2011, American family physician.

Self-rated health as a tool for estimating health-adjusted life expectancy among patients newly diagnosed with localized prostate cancer: a preliminary study

P. Schellhammer, John W. Davis, H. Beydoun, 2011, Quality of Life Research.

Prostate cancer grade assignment: the effect of chronological, interpretive and translation bias.

D. Bostwick, P. Schellhammer, F. Kondylis, 2003, Journal of Urology.

Randomized trial of active cellular immunotherapy with sipuleucel-T in androgen dependent prostate cancer (ADPC)

P. Schellhammer, T. Beer, J. Corman, 2007 .

Upper tract transitional cell carcinoma following treatment of superficial bladder cancer with BCG.

P. Schellhammer, G. Eure, E. B. Miller, 1993, Urology.

Separated pyelocolocutaneous diversion after bilateral ureterectomy and radical cystectomy for transitional cell carcinoma.

P. Schellhammer, K. J. Carney, 1997, Urology.

Pelvic complications after interstitial and external beam irradiation of urologic and gynecologic malignancy

P. Schellhammer, G. Jordan, A. El-Mahdi, 1986, World Journal of Surgery.

Analysis of prostatic tumor cultures using fluorescence in-situ hybridization (FISH).

P. Schellhammer, D. Peehl, A. Brothman, 1992, Cancer genetics and cytogenetics.

A Urologist's Personal View of Prostate Cancer.

P. Schellhammer, 2016, Turkish journal of urology.

Treater to target: a urologist's personal experience with prostate cancer.

P. Schellhammer, 2012, Journal of the National Cancer Institute. Monographs.

Four cases of metastases to the penis and a review of the literature.

P. Schellhammer, E. Robey, 1984, The Journal of urology.

Histological characteristics of prostatic biopsies after 125iodine implantation.

P. Schellhammer, A. El-Mahdi, L. Ladaga, 1980, The Journal of urology.

Summary of transitional cell carcinoma of the urethra in men having cystectomy for bladder cancer (by Paul F. Schellhammer, MD, and Willet F. Whitmore, Jr, MD). 1976.

P. Schellhammer, R. Stephenson, R. Bracken, 1997, Seminars in urologic oncology.

Immediate adjuvant intravesical chemotherapy after transurethral resection of bladder tumor.

P. Schellhammer, 1998, Current opinion in urology.

What is the available evidence to support immediate adjuvant intravesical chemotherapy after transurethral resection of superficial transitional cell carcinoma of the bladder?

P. Schellhammer, 1998, Urologic oncology.

Optimization of initial prostate biopsy in clinical practice: sampling, labeling and specimen processing.

Samir S Taneja, Paul Schellhammer, H Ballentine Carter, 2013, The Journal of urology.

AUA/Optimal Techniques of Prostate Biopsy and Specimen Handling

P. Schellhammer, S. Taneja, D. Troyer, 2013 .

External sphincterotomy: rational for the procedure and experiences with 150 patients

P. Schellhammer, R. C. Bunts, R. Hackler, 1974, Paraplegia.

Flt3-ligand induces transient tumor regression in an ectopic treatment model of major histocompatibility complex-negative prostate cancer.

P. Schellhammer, G. Wright, K. Somers, 2000, Cancer research.

Periprostatic Lidocaine Infiltration and/or Synthetic Opioid (Meperidine or Tramadol) Administration Have No Analgesic Benefit during Prostate Biopsy

P. Schellhammer, E. Akbay, E. Ulusoy, 2004, Urologia Internationalis.

Complications of Pelvic Lymphadenectomy and Interstitial Irradiation of A2 Tumors

P. Schellhammer, 1991 .

Cytogenetic analysis of four primary prostatic cultures.

P. Schellhammer, A. Brothman, K. Somers, 1989, Cancer genetics and cytogenetics.

Impact of the tumor microenvironment on host infiltrating cells and the efficacy of flt3-ligand combination immunotherapy evaluated in a treatment model of mouse prostate cancer

Richard P. Ciavarra, P. Schellhammer, George L. Wright, 2003, Cancer Immunology, Immunotherapy.

Segmental testicular ischaemia mimicking testicular tumor.

P. Schellhammer, J. W. Davis, W. G. Horstman, 1997, British Journal of Urology.

Laparoscopic radical prostatectomy: decreasing the learning curve using a mentor initiated approach.

P. Schellhammer, I. Tuerk, M. Fabrizio, 2003, The Journal of urology.

Müllerian duct cysts: conservative management.

P. Schellhammer, C. Devine, J. Stecker, 1987, Urology.

Giant hydronephrosis of a duplex system associated with ureteral ectopia.

P. Schellhammer, R. Whitmore, 1989, Journal of Urology.

Ex situ study of the effectiveness of enucleation in patients with renal cell carcinoma.

P. Schellhammer, L. Ladaga, R. Woolfitt, 1988, The Journal of urology.

Primary mucus-secreting adenocarcinoma of the renal pelvis.

P. Schellhammer, L. Ladaga, J. Copeland, 1979, Southern medical journal.

Combined androgen blockade for the treatment of metastatic cancer of the prostate.

P. Schellhammer, 1996, Urology.

[Laparoscopic radical cystectomy with intracorporeal creation of a continent urinary diversion. Future or present?].

P. Schellhammer, S. Loening, B. Schönberger, 2002, Der Urologe. Ausg. A.

Renal metastases from carcinoma of the lung.

P. Schellhammer, W. E. Becker, 1986, British journal of urology.

I–125 interstitial implantation for prostate cancer. What have we learned 10 years later?

D. Kuban, P. Schellhammer, A. El-Mahdi, 1989, Cancer.

Venous thromboembolism.

P. Schellhammer, M. A. Fogle, D. W. Brenner, 1989, The Journal of urology.

Overexpression of α-defensin is associated with bladder cancer invasiveness

A. Vlahou, P. Schellhammer, John W. Davis, 2006 .

Hyperplasia and Healthy Men ProstateAlgorithm Distinguishes Prostate Cancer from Benign Serum Protein Fingerprinting Coupled with a Pattern-matching Updated

P. Schellhammer, Y. Yasui, B. Adam, 2002 .

Improved detection of recurrent bladder cancer using the Bard BTA stat Test.

P. Schellhammer, W. Ellis, D. Lamm, 1998, Urology.

Quality of Life: Impact of Prostate Cancer and its Treatment

P. Schellhammer, John W. Davis, 2003 .

Reevaluation of prostate biopsy after definitive radiation therapy.

P. Schellhammer, A. El-Mahdi, L. Ladaga, 1993, Urology.

Assessment of endpoints for clinical trials for localized prostate cancer.

P. Schellhammer, P. Scardino, I. Thompson, 1997, Urology.

Prostate biopsy after definitive treatment by interstitial 125iodine implant or external beam radiation therapy.

P. Schellhammer, T. Schultheiss, A. El-Mahdi, 1987, The Journal of urology.

Male external genitals reconstruction following tumor ablation

P. Schellhammer, G. Jordan, D. Gilbert, 1992, World Journal of Urology.

Epithelioid sarcoma of the penis.

P. Schellhammer, P. Devine, A. Leviav, 1988, Clinics in plastic surgery.

Complex-negative Prostate Cancer Treatment Model of Major Histocompatibility Flt 3-Ligand Induces Transient Tumor Regression in an Ectopic Updated

P. Schellhammer, George L. Wright, K. Somers, 2000 .

Advances in Brief Flt 3-Ligand Induces Transient Tumor Regression in an Ectopic Treatment Model of Major Histocompatibility Complex-negative Prostate Cancer 1

P. Schellhammer, George L. Wright, K. Somers, 2000 .

Intravesical chemotherapy with gamma linolenic acid becomes a reality.

P. Schellhammer, 1998, The Journal of urology.

Overexpression of alpha-defensin is associated with bladder cancer invasiveness.

A. Vlahou, P. Schellhammer, John W. Davis, 2006, Urologic oncology.

Principles, Hazards, and Precautions

P. Schellhammer, 1974 .

Surgical Management of Squamous Cell Carcinoma of the Penis

P. Schellhammer, D. Lynch, 2004, TheScientificWorldJournal.

OUTCOME AFTER INTRAVESICAL BCG IS NOT AFFECTED BY T1a/T1b SUBSTAGING

P. Schellhammer, F. Kondylis, P. Kolm, 1999 .

Intestinal strictures complicating preoperative radiation therapy followed by radical cystectomy.

P. Schellhammer, A. El-Mahdi, R. W. Hillyard, 1986, The Journal of urology.

Pelvic complications after definitive treatment of prostate cancer by interstitial or external beam radiation.

P. Schellhammer, A. El-Mahdi, 1983, Urology.

125Iodine implantation for carcinoma of the prostate: 5-year survival free of disease and incidence of local failure.

P. Schellhammer, T. Schultheiss, L. Ladaga, 1985, The Journal of urology.

Histochemical Studies of the Myocardium and Conduction System in Acquired Iron‐Storage Disease

P. Schellhammer, M. A. Engle, J. Hagstrom, 1967, Circulation.

External sphincterotomy: rationale for the procedure and experiences with 150 patients

P. Schellhammer, R. C. Bunts, R. Hackler, 1975 .

Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel.

P. Schellhammer, R. Kaplan, E. Hammond, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treater to Target: Experiences of a Prostate Cancer Participant

P. Schellhammer, 2011 .

An evaluation of bicalutamide in the treatment of prostate cancer.

P. Schellhammer, John W. Davis, 2004, Clinical prostate cancer.

RESEARCH HIGHLIGHTS: EBM from the Cochrane Library

T. Wilt, R. MacDonald, B. Kramer, 2009 .

Prognostic factors in stage D2 prostate cancer treated with a pure nonsteroidal antiandrogen

P. Schellhammer, G. Kennealey, M. Soloway, 1993, Cancer.

Continuous-infusion 5-fluorouracil and cisplatin for advanced/recurrent transitional cell cancer of the bladder: a Southwest Oncology Group trial.

P. Schellhammer, A. Einstein, E. Crawford, 1997, American journal of clinical oncology.

Comparison of transrectal fine-needle aspiration cytology and core needle biopsy in diagnosis of prostate cancer.

P. Schellhammer, S. Schlossberg, L. Ladaga, 1990, Urology.

Reply to P.H. Frankel et al

B. Kramer, P. Schellhammer, M. Somerfield, 2009 .

Five-alpha-reductase Inhibitors for prostate cancer prevention.

T. Wilt, R. MacDonald, B. Kramer, 2008, The Cochrane database of systematic reviews.

Fulminant hepatic failure associated with bicalutamide.

P. Schellhammer, 1997, Urology.

A dose-response study of the effect of flutamide on benign prostatic hyperplasia: results of a multicenter study.

F M Debruyne, P. Schellhammer, A. Tewari, 1996, Urology.

Prostate-specific antigen best practice policy--part I: early detection and diagnosis of prostate cancer.

C Coley, P. Schellhammer, I. Thompson, 2001, Urology.

Serum PSA decline after Casodex withdrawal.

P. Schellhammer, G. Kolvenbag, 1994, Urology.

Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry

P. Kantoff, M. Cooperberg, P. Schellhammer, 2020, Prostate Cancer and Prostatic Diseases.

The pursuit of prostate cancer in patients with a rising prostate-specific antigen and multiple negative transrectal ultrasound-guided prostate biopsies.

P. Schellhammer, M. B. Pryor, 2002, Clinical prostate cancer.

O Management of Patients with Bacilli Calmette-G & in-Refractory Carcinoma in Situ of the Urinary Bladder : Cost Implications of a Clinical Trial for Valruhicin

Liping, P. Schellhammer, Donald, 2005 .

PROSTATIC TUMOR RELAPSE IN PATIENTS WITH SUPERFICIAL BLADDER TUMORS: 15-YEAR OUTCOME

P. Schellhammer, 1999 .

Erattum: Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: Final report of a double-blind, randomized, multicenter trial (Urology (September 1997) 50 (330-336))

P. Schellhammer, N. Vogelzang, M. Soloway, 1998 .

Hemibody irradiation in advanced prostatic carcinoma.

D. Kuban, P. Schellhammer, A. El-Mahdi, 1991, The Urologic clinics of North America.

Deoxyribonucleic acid cytometric analysis of prostate core biopsy specimens: relationship to serum prostate specific antigen and prostatic acid phosphatase, clinical stage and histopathology.

P. Schellhammer, M. Clements, P. Kolm, 1993, The Journal of urology.

BCG treatment of superficial transitional cell carcinoma.

P. Schellhammer, 1991, Urology.

Editorial: A worldwide View of Bladder Cancer

P. Schellhammer, 1997 .

Therapeutic strategies for local failure after radiation therapy for stage A-C carcinoma of the prostate

D. Kuban, P. Schellhammer, A. El-Mahdi, 1993 .

Massive intrascrotal fibrolipoma.

P. Schellhammer, J. Scarff, R. Huben, 1983, The Journal of urology.

The clinical and economic implications of specimen provenance complications in diagnostic prostate biopsies.

P. Schellhammer, J. Hornberger, K. Wojno, 2015, The Journal of urology.

Prospective longitudinal comparative study of health-related quality of life in patients undergoing invasive treatments for localized prostate cancer.

P. Schellhammer, John W. Davis, M. Fabrizio, 2005, Journal of endourology.

Local failure after definitive therapy for prostatic cancer.

P. Schellhammer, E. Robey, 1987, The Journal of urology.

Intermittent Androgen Suppression for Rising PSA Level After Radiotherapy

Joseph L. Chin, Celestia S. Higano, Fred Saad, 2013 .

Glansectomy: an alternative surgical treatment for Buschke‐Lowenstein tumours of the penis

P. Schellhammer, J.W. Davis, J.W. Davis, 2001, BJU international.

Potential benefit of improved local tumor control in patients with prostate carcinoma

D. Kuban, P. Schellhammer, A. El-Mahdi, 1995, Cancer.

Estimated potency of casodex: A problematic design [1] (multiple letters)

P. Schellhammer, J. Simard, N. Vogelzang, 1997 .

Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): Results of S9346 (INT-0162), an international phase III trial.

P. Schellhammer, I. Thompson, C. Tangen, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prostate-specific antigen best practice policy--part II: prostate cancer staging and post-treatment follow-up.

P. Schellhammer, I. Thompson, A. Zietman, 2001, Urology.

Morbidity and mortality of local failure after definitive therapy for prostate cancer.

D. Kuban, P. Schellhammer, A. El-Mahdi, 1989, The Journal of urology.

PSA for outcome prediction and posttreatment evaluation following radiation for prostate cancer: do we know how to use it?

D. Kuban, P. Schellhammer, A. El-Mahdi, 1998, Seminars in radiation oncology.

Triple course external beam radiotherapy for carcinoma of the prostate.

P. Schellhammer, A. El-Mahdi, C. Turalba, 1984, International journal of radiation oncology, biology, physics.

The COMPARE Registry: design and baseline patterns of care for men with biochemical failure after definitive treatment of localized prostate cancer.

John T. Wei, A. D'Amico, P. Schellhammer, 2010, Urology.

Percent free prostate-specific antigen values in men with recurrent prostate cancer after radical prostatectomy.

P. Schellhammer, J. Montie, G. Wright, 1998, Urology.

P. Schellhammer, A. El-Mahdi, J. P. Petersen, 1990, Urology.

The significance of post-irradiation prostate biopsy with long-term follow-up.

D. Kuban, P. Schellhammer, A. El-Mahdi, 1992, International journal of radiation oncology, biology, physics.

Pulmonary metastases from prostate cancer

P. Schellhammer, A. El-Mahdi, S. Fabozzi, 1995, Cancer.

Solitary lesions on bone scan in genitourinary malignancy.

P. Schellhammer, P F Schellhammer, E L Robey, 1984, The Journal of urology.

Quality of life after open or robotic prostatectomy, cryoablation or brachytherapy for localized prostate cancer.

P. Schellhammer, John W. Davis, M. Fabrizio, 2010, The Journal of urology.

The detection of prostate specific antigen, MHS-5, and other markers in invasive prostate cancer and seminal vesicle.

P. Schellhammer, S. Schlossberg, G. Wright, 1992, Journal of Urology.

Are three substages of clinical B prostate carcinoma useful in predicting disease-free survival?

P. Schellhammer, C. Philput, L. Ladaga, 1990, Urology.

Advances in Brief Quantitation of Serum Prostate-specific Membrane Antigen by a Novel Protein Biochip Immunoassay Discriminates Benign from Malignant Prostate Disease 1

P. Schellhammer, E. Dalmasso, B. Adam, 2001 .

The role of routine followup bone scans after definitive therapy of localized prostatic cancer.

P. Schellhammer, R. Huben, 1982, The Journal of urology.

Reply by Author

P. Schellhammer, 2009 .

Abstract of ASTRO scientific posters to be presented poster sessionSix-year experience with triple course irradiation for carcinoma of the prostate

P. Schellhammer, A. El-Mahdi, C. Turalba, 1984 .

Fifteen-year minimum follow-up of a prostate brachytherapy series: comparing the past with the present.

D. Bostwick, D. Kuban, P. Schellhammer, 2000, Urology.

Legends in Urology.

P. Schellhammer, 2016, The Canadian journal of urology.

Prognosis in patients with local recurrence after definitive irradiation for prostatic carcinoma

D. Kuban, P. Schellhammer, A. El-Mahdi, 1989, Cancer.

Prostatorectal fistula 14 years following brachytherapy for prostate cancer.

P. Schellhammer, J. W. Davis, 2001, The Journal of urology.

Transitional cell carcinoma: cause of refractory cancer of prostate.

P. Schellhammer, A. El-Mahdi, J. Wendelken, 1979, Urology.

Bilateral testicular rupture: report of a case with an unusual presentation.

P. Schellhammer, S. Warden, 1978, The Journal of urology.

Pyelocancerous backflow: a radiologic finding in renal malignancy.

P. Schellhammer, C. Devine, J. Copeland, 1976, The Journal of urology.

Mortality in prostatic carcinoma

D. Kuban, P. Schellhammer, A. El-Mahdi, 1989 .

Relative potency of bicalutamide (Casodex) and flutamide (Eulexin)

P. Schellhammer, S. Fabozzi, 1999 .

Local failure after definitive radiation or surgical therapy for carcinoma of the prostate and options for prevention and therapy.

D. Kuban, P. Schellhammer, A. El-Mahdi, 1991, The Urologic clinics of North America.

Single center experience with third-generation cryosurgery for management of organ-confined prostate cancer: critical evaluation of short-term outcomes, complications, and patient quality of life.

P. Schellhammer, M. Fabrizio, B. Barone, 2007, Journal of endourology.

Prostatic carcinoma with diffuse cutaneous metastases.

P. Schellhammer, 1978, Urology.

Proteinchip® surface enhanced laser desorption/ionization (SELDI) mass spectrometry: a novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures

G. Wright, L. Cazares, S. Leung, 1999, Prostate Cancer and Prostatic Diseases.

Overall survival (OS) of African-American (AA) and Caucasian (CAU) men who received sipuleucel-T for metastatic castration-resistant prostate cancer (mCRPC): Final PROCEED analysis.

P. Kantoff, M. Cooperberg, P. Schellhammer, 2019, Journal of Clinical Oncology.

High-Grade Prostate Cancer and the Prostate Cancer Prevention Trial

P. Schellhammer, C. Logothetis, 2008, Cancer Prevention Research.

Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

P. Kantoff, P. Schellhammer, C. Redfern, 2010, The New England journal of medicine.

Zoladex versus orchiectomy in treatment of advanced prostate cancer: a randomized trial. Zoladex Prostate Study Group.

P. Schellhammer, N. Vogelzang, M. Soloway, 1991, Urology.

A Urologist's Personal View of Prostate Cancer.

P. Schellhammer, 2016, Turkish journal of urology.

Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study.

P. Schellhammer, S. Culp, Michael Williams, 2014, European urology.

Clinical trials in prostate cancer

P. Schellhammer, P. Schellhammer, 2003, Harvard men's health watch.

Open Label Phase II Study of Enzalutamide With Concurrent Administration of Radium 223 Dichloride in Patients With Castration-Resistant Prostate Cancer.

P. Schellhammer, N. Shore, R. Tutrone, 2020, Clinical genitourinary cancer.

A novel prostate carcinoma‐associated glycoprotein complex (PAC) recognized by monoclonal antibody turp‐27

P. Schellhammer, George L. Wright, G. Lipford, 1991, International journal of cancer.

Are monotherapy options reasonable for T3 prostate cancer?

P. Schellhammer, D. Lynch, 1997, Seminars in urologic oncology.

Human prostate tissue antigens defined by murine monoclonal antibodies.

P. Schellhammer, G. Wright, J. J. Starling, 1986, Cancer research.

Management of patients with Bacilli Calmette-Guérin-refractory carcinoma in situ of the urinary bladder: cost implications of a clinical trial for valrubicin.

A. Marchetti, P. Schellhammer, D. Lamm, 2000, Clinical therapeutics.